
Opinion|Videos|August 1, 2024
Importance of Patient-Reported Outcomes
Author(s)Steven D. Nathan, MD
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the potential impact of these novel treatments on disease progression, mortality, and patient-reported outcomes such as quality of life, survival time, and functional status?
- An important consideration in drug development is understanding the impact on patient-reported outcomes and quality of life. How are the clinical trials for idiopathic pulmonary fibrosis agents incorporating these measures?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Sexual Dysfunction From Cancer Is Widespread—and Many Don’t Know That Before Treatment, Data Show
3
Enzalutamide Combo Improves OS in Prostate Cancer Without Sacrificing Quality of Life: Stephen Freedland, MD
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5